ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

SYH2053

A development code. Also written as “SYH2053 Injection” and “SYH2053 injection”.

Its studies are mostly in Hyperlipoproteinemia Type II · Renal Insufficiency · Hyperlipidemias, led by CSPC Pharmaceutical Group.

Drug pageSYH2053: every studyAll 5 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Feb 12, 20265 company-led studies, 4 open or runningNext primary completion: Jul 15, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
CSPC Pharmaceutical Group54 open or runningphase 3since Feb 12, 2026Dec 20, 2023Jul 15, 2027phase 1 · NCT07938034
  • Named in CSPC Pharmaceutical Group’s own pipeline as SYH2053 (PCSK9 siRNA), phase 3, as of Aug 20, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 20, 2023First study: phase 1 study in HyperlipidemiasFirst studyNCT06229548 · 39 enrolled · China
  2. Feb 12, 2026Phase 3 study in Hyperlipoproteinemia Type IIPhase 3 reachedNCT07421297 · 760 planned · China
  3. Mar 6, 2026Phase 3 study in Heterozygous Familial Hypercholesterolemia (HeFH)NCT07465263 · 135 planned · China
  4. Jul 2, 2026Phase 1 study in Renal InsufficiencyNCT07938034 · 24 planned · China
  5. Nov 11, 2026Phase 1 study in Hepatic ImpairmentNCT07943520 · 24 planned · China

Ahead

  1. Jul 15, 2027Primary completion: phase 1 study in Renal InsufficiencyNCT07938034
  2. Aug 15, 2027Primary completion: phase 1 study in Hepatic ImpairmentNCT07943520
  3. Dec 31, 2027Primary completion: phase 3 study in Hyperlipoproteinemia Type IINCT07421297
  4. Feb 28, 2028Primary completion: phase 3 study in Heterozygous Familial Hypercholesterolemia (HeFH)NCT07465263

TargetBeta

PCSK9 →read by rule
“SYH2053 is a synthetic, chemically modified small interfering ribonucleic acid (siRNA) targeting proprotein convertase subtilisin kexin type 9 (PCSK9) messenger ribonucleic acid (mRNA) with a covalently attached triantennary N-acetylgalactosamine (GalNAc) ligand.”study text, by rule · the study

Other programs on PCSK9

ProgramCompanyFurthest phaseStudies
alirocumabruleSanofiphase 448
evolocumabruleAmgenphase 445
inclisiranruleNovartisphase 437
lerodalcibeprulelib-therapeutics-llcphase 314
tafolecimabruleInnovent Biologicsphase 38
recaticimabruleJiangsu HengRui Medicinephase 37
QLC7401ruleQilu Pharmaceuticalphase 35
SAL003ruleShenzhen Salubris Pharmaceuticalsphase 33
VERVE-102Eli Lillyphase 22
DNV001rulehangzhou-dinovate-biotech-co-ltdphase 21
RBD7022ruleQilu Pharmaceuticalphase 12

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07943520Hepatic Impairment · China1RecruitingAug 15, 202724
NCT07938034Renal Insufficiency · China1RecruitingJul 15, 202724
NCT07465263Heterozygous Familial Hypercholesterolemia (HeFH) · China3RecruitingFeb 28, 2028135
NCT07421297Hyperlipoproteinemia Type II · China3RecruitingDec 31, 2027760
NCT06229548Hyperlipidemias · China1CompletedDec 23, 202439

How it is read

Names in the registry

  • “SYH2053”, 3 entries
  • “SYH2053 Injection”, 1 entry
  • “SYH2053 injection”, 1 entry

Codes read as this program: SYH2053.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.